Clinical Trials Logo

Filter by:
NCT ID: NCT05757505 Not yet recruiting - Clinical trials for Intracranial Atherosclerosis

The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis

Start date: March 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of symptomatic intracranial atherosclerotic stenosis.

NCT ID: NCT05753865 Not yet recruiting - Clinical trials for Advanced Breast Cancer

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Start date: May 1, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety in patients with advanced breast cancer treated with SYHX2011 versus paclitaxel for injection (albumin-bound).

NCT ID: NCT05751824 Not yet recruiting - Clinical trials for Artificial Intelligence

Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients

Start date: February 26, 2023
Phase: N/A
Study type: Interventional

In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups were compared.

NCT ID: NCT05751538 Not yet recruiting - Bronchiectasis Clinical Trials

Artificial Intelligence in Computed Tomography for Quantifying Lung Changes of Bronchiectasis Patients

Start date: March 1, 2023
Phase:
Study type: Observational

Bronchiectasis is a chronic respiratory disease characterized by permanent bronchiectasis.The incidence and prevalence of bronchiectasis have assumed continuously grows in global. Chest computed tomography (CT) remains the imaging standard for demonstrating cystic fibrosis (CF) airway structural disease in vivo. However, visual scoring systems as an outcome measure are time consuming, require training and lack high reproducibility. Our objective was to validate a fully automated artificial intelligence (AI)-driven scoring system of CF lung disease severity.

NCT ID: NCT05751512 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Start date: March 2023
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.

NCT ID: NCT05749874 Not yet recruiting - Hypertension Clinical Trials

Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

ABCD
Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine on preventing cardiovascular disease and diabetes mellitus among individuals with high cardiometabolic risk in China.

NCT ID: NCT05747729 Not yet recruiting - Clinical trials for Neuroendocrine Carcinoma

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Start date: February 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a prospective open-label, single-arm, single-center clinical study. Patients with neuroendocrine carcinoma who had not previously received standard therapy were enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. This clinical trial evaluates the efficacy and safety of surufatinib and serplulimab combined with standard chemotherapy (Platinum/Etoposide) in neuroendocrine carcinoma.

NCT ID: NCT05747716 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Start date: February 28, 2023
Phase: Phase 2
Study type: Interventional

The study is a phase II clinical study. The purpose of the study is to evaluate the efficacy and safety of SBRT combined with Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC.

NCT ID: NCT05746728 Not yet recruiting - Clinical trials for Metastatic Triple-negative Breast Cancer

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Start date: April 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC). The study will be conducted in two parts; Safety lead-in phase and dose expansion phase.

NCT ID: NCT05745740 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Start date: April 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation.